MedTrace Logo

Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer

NCT03022162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-10-14

No results posted yet for this study

Summary

Since its introduction in the 1970s, Paclitaxel has been used as an effective anticancer agent against lung, breast, ovarian, leukopenia and liver cancer. But, Paclitaxel-induced peripheral neuropathy is the major dose-limiting side effect of paclitaxel.Paclitaxel induced peripheral neuropathy most commonly presents as

1. Pain
2. Burning,
3. Tingling ("pins and needles" feeling) or electric/shock-like pain,
4. Hyperalgesia,
5. Allodynia,
6. Increased sensitivity to cold or heat These symptoms are classically seen symmetrically in the distal extremities (glove and stocking distribution).

Most adverse effects associated with chemotherapy are ameliorated after cessation of the therapy, but CIPN may persist in the longterm, with 30 % patients having CIPN related symptoms beyond 6 months after completion of chemotherapy7.Understanding the epidemiology of neuropathic pain in breast cancer patients has high clinical and public health significance.

Conditions

  • Breast Cancer Female
  • Neuropathic Pain

Sponsors & Collaborators

  • Tata Memorial Centre

    lead OTHER

Principal Investigators

  • Anuja Bidkar, DNBAnes · Tata Memorial Centre

  • Aparna Chatterjee, MDAnes · Tata Memorial Centre

  • Sudeep Gupta, DMOnco · Tata Memorial Centre

  • Parmanand Jain, MDAnes · Tata Memorial Centre

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03022162 on ClinicalTrials.gov